SAN FRANCISCO--(BUSINESS WIRE)-- Ivivi Health Sciences, LLC, an innovative medical technology company that designs, develops and markets non-invasive anti-inflammatory and regenerative technologies, has announced new leadership appointments to its executive team.
In the C-suite, President and Chief Operating Officer Kathryn Clubb has been promoted to the position of Chief Executive Officer. Cofounder Steven M. Gluckstern will continue to provide management and guidance as the company’s Chairman.
“Kathryn has long been integral to Ivivi’s strategy, development and success,” said Gluckstern. “This promotion acknowledges her contributions, skills and the critical leadership she has brought to Ivivi and our subsidiaries. I look forward to continuing our collaborative management approach as she assumes the role of CEO.”
“Over the past year Ivivi has made remarkable headway preparing to bring electrotherapy solutions to key markets including orthopedics,” said Clubb. “We are working to expand access to our technology for more patients in multiple indications. Our goal is to make our targeted, non-invasive, non-drug therapies the standard of care for all inflammatory conditions, acute and chronic, revolutionizing health care delivery and reducing the cost of care.”
In order to help direct research initiatives for Ivivi and its subsidiaries, the company has also announced that veteran drug developer, industry executive and cardiologist, Ted W. Love, MD, has been appointed to the position of Senior Medical Advisor. In this capacity Dr. Love will provide strategic scientific guidance to ongoing clinical trials, prepare future research programs and advise Ivivi’s management team on potential new indications for deploying its technology. Over Dr. Love’s distinguished career he has served in senior management positions and on executive boards for leading biotechnology and medical technology organizations including Genentech, Affymax, Onyx Pharmaceuticals and the California Institute for Regenerative Medicine. Dr. Love earned his medical degree at Yale Medical School and completed his residency in internal medicine and cardiology at Harvard Medical School and Massachusetts General Hospital.
“Electrotherapy technology is rapidly evolving from an unfamiliar treatment technique to an important component of patient care,” said Dr. Love. “I’m very excited to be at the cutting edge of this emerging treatment paradigm as we amass additional clinical knowledge and explore new ways to help patients with this technology.”
About Ivivi Health Sciences, LLC
Ivivi Health Sciences is a leader in the field of inductive electrotherapy. Its products have a demonstrated mechanism of action and proven clinical outcomes, and has been granted FDA clearance for the reduction of post-surgical pain and edema. The company is currently focused on the post-operative orthopedic market through its subsidiary, AMP Orthopedics, with plans underway to expand the therapeutic indications for its devices to treat osteoarthritis and other degenerative inflammatory conditions. Among Ivivi’s advisors are some of the most accomplished and respected scientists, researchers and clinicians in the country. Ivivi was founded in 2010 by Steven M. Gluckstern and Kathryn Clubb. The company is headquartered in San Francisco. For more information, please visit: http://www.ivivihealthsciences.com
Contact:
Torch Communications, LLC
Jeremiah Hall, 415-349-5016
jeremiah@torchcommunications.com
